Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051436 · ClinicalTrials.gov registry record · Phase 4
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
A Phase 4 study of Obesity and Pre Diabetes, sponsored by Philip Kern.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT05051436 is a Phase 4 study of Obesity and Pre Diabetes that is actively recruiting participants, run by Philip Kern. The registered enrollment target is 96 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05051436, a Phase 4 study of Obesity and Pre Diabetes, is actively recruiting participants, sponsored by Philip Kern.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mirabegron 50 MG
- DRUG Tadalafil 10 MG
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05051436
The ClinicalTrials.gov registry entry for NCT05051436 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05051436 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05051436 about?
NCT05051436 is a clinical study titled "The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics". The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will c...
What is the current status of trial NCT05051436?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2021-12-13. Estimated completion is 2026-08.
What conditions does trial NCT05051436 study?
This clinical trial studies the following conditions: Obesity, Pre Diabetes.
What interventions are being tested in trial NCT05051436?
The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG), Tadalafil 10 MG (DRUG).
Who is sponsoring clinical trial NCT05051436?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05051436 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
A Study of a Novel Precision Medicine Approach For Obesity
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.